Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
14 Juni 2018 - 2:00PM
Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody immunotherapies to
address serious infectious diseases, today announced that it has
entered into an agreement under which BB200, LLC, a portfolio
company of Bravos Biosciences, LLC, has secured an exclusive,
worldwide preclinical development license, and an option to a
clinical development and commercialization license to selected
monoclonal antibodies (mAbs) targeting K. pneumoniae that were
discovered by Arsanis in its ASN300 program, including lead
preclinical development candidate, ASN-5. In April 2018, Arsanis
entered into a similar agreement for its ASN200 program,
targeting E. coli, with Bravos Biosciences subsidiary BB100,
LLC.
“Gram-negative bacteria are responsible for some of the most
lethal and antibiotic-resistant hospital-acquired infections and we
are excited that the expert team at Bravos Biosciences will
continue to move these non-antibiotic monoclonal antibody programs
forward,” said René Russo, chief executive officer of Arsanis.
“With the successful out-licensing of antibodies from our ASN200
and ASN300 programs, we have completed our strategic goal of
focusing our development pipeline while ensuring the potential
advancement of these important gram-negative targeted mAbs under
the leadership of a well-known expert team. This transaction
allows Arsanis to focus on execution of our lead program, ASN100,
currently in Phase 2 development for the prevention of S. aureus
pneumonia in high-risk, mechanically ventilated patients, and on
ASN500 for respiratory syncytial virus infection, slated to begin
clinical development in 2019.”
Under the agreement, Arsanis has granted BB200 the exclusive
right to conduct further preclinical development activities on
licensed mAbs, with an option to enter into an exclusive global
development and commercial license. Arsanis retains the rights to
all other mAbs developed in the ASN300 program.
About ASN300 and ASN-5The ASN300 program is
currently in preclinical development. As part of this program,
Arsanis is developing monoclonal antibodies, including ASN-5, which
have demonstrated rapid and targeted activity through various modes
of action and provide high efficacy in relevant animal models of
severe K. pneumoniae infections.
About BB200BB200 is a fully owned subsidiary of
Bravos Biosciences, LLC. Paul G.
Ambrose, Pharm.D., F.I.D.S.A., currently
serves as president of the Institute for Clinical Pharmacodynamics
(ICPD, Schenectady, NY). Both Bravos Biosciences and ICPD are
cofounded by Drs. Ambrose, Sujata M. Bhavnani and Christopher M.
Rubino. The team’s areas of scientific inquiry primarily
involve anti-infective translational science, with the goal of
improving patient care through the application of
pharmacokinetic-pharmacodynamic (PK-PD) principles. Dr. Ambrose has
held academic appointments at the University of Oxford and the
University at Buffalo as well as past industry positions including
at Bristol Myers Squibb. Dr. Ambrose holds a Pharm.D. from the
University of the Pacific and completed a Post-Doctoral Fellowship
in infectious diseases at Hartford Hospital.
About ArsanisArsanis, Inc. is a
clinical-stage biopharmaceutical company focused on applying
monoclonal antibody (mAb) immunotherapies to address serious
infectious diseases. A deep understanding of the pathogenesis of
infection, paired with access to what the company believes to be
some of the most advanced mAb discovery techniques and platforms
available today, has positioned Arsanis to further its
goal of building and advancing a pipeline of novel mAbs with
multiple mechanisms of action and high potency against their
intended targets. The company’s lead clinical program, ASN100, is
aimed at serious Staphylococcus aureus infections and is being
evaluated in a Phase 2 clinical trial for the prevention of S.
aureus pneumonia in high-risk, mechanically ventilated
patients. In addition to ASN100, its preclinical pipeline is
comprised of mAbs targeting multiple serious bacterial and viral
pathogens, including respiratory syncytial virus (RSV).
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis
Biosciences GmbH).
For more information, please visit the Arsanis website at
www.arsanis.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding Arsanis’ plans, strategies and expectations for the
clinical development of its mAb programs; the expected benefits of
the option and license agreement for ASN 300; and the potential
benefit of its strategic plans and focus. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “would,” “could,” “potential,” “possible,”
“hope,” “strategy,” “milestone,” “will,” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results to differ
materially from Arsanis' current expectations and beliefs. For
example, there can be no guarantee that any mAb programs Arsanis is
developing will successfully commence or complete necessary
preclinical and clinical development phases, or that development of
any of Arsanis' product candidates (including the product
candidates Arsanis chooses to out-license) will successfully
continue. There can be no guarantee that any positive developments
in Arsanis' business will result in stock price appreciation.
Management's expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks
and uncertainties relating to a number of other important factors,
including: Arsanis' results of clinical trials and preclinical
studies, including subsequent analysis of existing data and new
data received from ongoing and future studies; the content and
timing of decisions made by the U.S. FDA and other regulatory
authorities, investigational review boards at clinical trial sites
and publication review bodies; Arsanis' ability to obtain and
maintain requisite regulatory approvals and to enroll patients in
its planned and ongoing clinical trials; unplanned cash
requirements and expenditures; competitive factors; Arsanis'
ability to obtain, maintain and enforce patent and other
intellectual property protection for any product candidates it is
developing; Arsanis' ability to maintain key collaborations; and
general economic and market conditions. These and other risks are
described in greater detail under the caption "Risk Factors"
included in Arsanis’ public filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Arsanis
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Media Contact: Jennifer Paganelli,
347-658-8290 jpaganelli@purecommunications.com
Investor Contact:Michael Gray,
781-819-5201Chief Operating and Chief Financial
Officermike.gray@arsanis.com
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024